重组Anti-Alpha-synuclein (phospho S129)抗体[MJF-R13 (8-8)] (ab168381)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [MJF-R13 (8-8)] to Alpha-synuclein (phospho S129)
- Suitable for: WB
- Reacts with: Human
Related conjugates and formulations
概述
-
产品名称
Anti-Alpha-synuclein (phospho S129)抗体[MJF-R13 (8-8)]
参阅全部 Alpha-synuclein 一抗 -
描述
兔单克隆抗体[MJF-R13 (8-8)] to Alpha-synuclein (phospho S129) -
宿主
Rabbit -
特异性
This antibody only detects alpha Synuclein phosphorylated on Ser129.
-
经测试应用
适用于: WBmore details
不适用于: Flow Cyt,ICC/IF,IHC-P or IP -
种属反应性
与反应: Human -
免疫原
Synthetic peptide within Human Alpha-synuclein (phospho S129). The exact sequence is proprietary.
Database link: P37840 -
阳性对照
- Recombinant alpha-synuclein, expressed in BL21 bacterial cells in the presence of Human Polo-Like Kinase 2; HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein.
-
常规说明
Alpha-synuclein was the first gene to be linked to Parkinson’s disease (PD) and remains the most promising link to PD pathogenesis, where there is genetic evidence that it may play a causal role. In the brain, alpha-synuclein is concentrated in presynaptic nerve terminals. The deposition of the abundant presynaptic brain protein alpha-synuclein as fibrillary aggregates in neurons or glial cells is a hallmark lesion in a subset of neurodegenerative disorders. These disorders include Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy, collectively referred to as synucleinopathies. Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha-synuclein and ubiquitin.
Recent studies also indicate that alpha-synuclein undergoes post-translational modification. Though the role of many of these modifications is still under investigation, phosphorylation at Serine 129 may affect alpha-synuclein aggregations and may also serve as marker of disease pathogenesis. With the advent of this phospho-specific Serine 129 antibody, The Michael J. Fox Foundation hopes to ensure that the putative role of this modification can be further examined by all researchers.This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This antibody was developed with support from The Michael J. Fox Foundation.
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
存储溶液
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol, 0.05% BSA -
Concentration information loading...
-
纯度
Protein A purified -
克隆
单克隆 -
克隆编号
MJF-R13 (8-8) -
同种型
IgG -
研究领域
相关产品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
应用
The Abpromise guarantee
Abpromise™承诺保证使用ab168381于以下的经测试应用
“应用说明”部分 下显示的仅为推荐的起始稀释度;实际最佳的稀释度/浓度应由使用者检定。
应用 | Ab评论 | 说明 |
---|---|---|
WB | (3) |
1/1000. Predicted molecular weight: 14 kDa.
|
说明 |
---|
WB
1/1000. Predicted molecular weight: 14 kDa. |
靶标
-
功能
May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. -
组织特异性
Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals. -
疾病相关
Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
Parkinson disease 1
Parkinson disease 4
Dementia Lewy body -
序列相似性
Belongs to the synuclein family. -
结构域
The 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments. -
翻译后修饰
Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
Ubiquitinated. The predominant conjugate is the diubiquitinated form.
Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure. -
细胞定位
Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons. - Information by UniProt
-
数据库链接
- Entrez Gene: 6622 Human
- Omim: 163890 Human
- SwissProt: P37840 Human
- Unigene: 21374 Human
-
别名
- Alpha synuclein antibody
- Alpha-synuclein antibody
- Alpha-synuclein, isoform NACP140 antibody
see all
图片
-
All lanes : Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381)
Lane 1 : In vitro kinase assay of Alpha Synuclein phosphorylation using His tagged human full length recombinant alpha-synuclein protein in the presence of PLK2 (Polo-like kinase 2) but absence of ATP
Lane 2 : In vitro kinase assay of Alpha Synuclein phosphorylation using His tagged human full length recombinant alpha-synuclein protein in the presence of ATP but absence of PLK2 (Polo-like kinase 2)
Lane 3 : In vitro kinase assay of Alpha Synuclein phosphorylation using His tagged human full length recombinant alpha-synuclein protein in the presence of PLK2 (Polo-like kinase 2) and ATP
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 14 kDa
Observed band size: 17 kDa why is the actual band size different from the predicted?Blocking and Diluting buffer and concentration - 5% NFDM/TBST
Exposure time: 5 seconds
-
Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) at 1/2000 dilution + Mouse cortical neuron lysate at 30 µg
Secondary
Goat anti-rabbit IgG (H+L) HRP
Developed using the ECL technique.
Predicted band size: 14 kDa
Exposure time: 5 minutesLysate prepared in PBS + 1% Triton X-100. Membrane fixed with 0.4% PFA in PBS for 30 min prior to blocking.
Primary incubation for 12 hours at 4°C.
-
All lanes : Anti-Alpha-synuclein (phospho S129) antibody [MJF-R13 (8-8)] (ab168381) at 1/1000 dilution
Lane 1 : Recombinant alpha Synuclein expressed in BL21 bacterial cells
Lane 2 : Recombinant alpha Synuclein expressed in BL21 bacterial cells, in the presence of Human Polo-Like Kinase 2
Lane 3 : HEK whole cell lysates, stably-transfected with Polo-Like Kinase 2 and alpha Synuclein
Predicted band size: 14 kDa
数据表及文件
-
SDS download
-
Datasheet download
文献 (39)
ab168381 被引用在 39 文献中.
- Fanning S et al. Lipase regulation of cellular fatty acid homeostasis as a Parkinson's disease therapeutic strategy. NPJ Parkinsons Dis 8:74 (2022). PubMed: 35680956
- Zinnen AD et al. Alpha-synuclein and tau are abundantly expressed in the ENS of the human appendix and monkey cecum. PLoS One 17:e0269190 (2022). PubMed: 35687573
- Magalhães P & Lashuel HA Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. NPJ Parkinsons Dis 8:93 (2022). PubMed: 35869066
- Lackie RE et al. Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo. Acta Neuropathol 144:881-910 (2022). PubMed: 36121476
- Jin M et al. DOPAnization of tyrosine in α-synuclein by tyrosine hydroxylase leads to the formation of oligomers. Nat Commun 13:6880 (2022). PubMed: 36371400